Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Pancreatic Cancer.

(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

For patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer ...

The FDA approved a subcutaneous injection version of Bristol Myers Squibb nivolumab and hyaluronidase-nvhy for the treatment of several cancers including melanoma, non-small cell lung cancer and renal ...

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...

Results from the phase 3 TiNivo-2 trial suggest that immune checkpoint inhibitor rechallenge should generally be discouraged ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

Bristol Myers Squibb BMY announced that the European Commission has approved the combination of its blockbuster ...

Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and ...

The Food and Drug Administration announced it has approved nivolumab and hyaluronidase-nvhy, Opdivo Qvantig, from Bristol Myers (BMY) Squibb, ...